Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?

Regeneron reported first-quarter revenue of $3.6 billion, up 19% year over year and ahead of the $3.48 billion consensus, with adjusted EPS rising 15% to $9.47. While Eylea sales fell 10% to $941 million, Libtayo sales jumped 54% to $438 million and Dupixent sales rose 36% to $1.6 billion, supporting a new $3 billion buyback authorization. The company also gained FDA accelerated approval for Otarmeni and has more than 50 therapies in its pipeline, though the stock remains down more than 11% year to date.

Analysis

The setup is less about a single-quarter beat and more about Regeneron re-rating from a mature one-product story into a multi-driver cash compounding platform. The key second-order effect is that Dupixent and Libtayo are now doing the heavy lifting while Eylea transitions from a growth engine to a managed decline, which usually compresses downside volatility in the earnings base once investors accept the mix shift. That changes the stock’s sensitivity: future multiple expansion is now more tied to pipeline probability and capital return discipline than to legacy ophthalmology sales.

The more interesting issue is competitive timing. Vabysmo pressure matters, but the market is likely underestimating how quickly Eylea HD can partially offset share loss by moving the franchise up the value chain, especially if prescribers prefer higher-convenience dosing in a cost-conscious environment. Meanwhile, Regeneron’s willingness to trade a low-probability U.S. commercial upside in Otarmeni for regulatory optionality suggests management is prioritizing portfolio-wide pricing stability over single-asset monetization — that is a favorable signal for the rest of the pipeline, particularly if policy risk becomes a larger overhang in 2H26.

Consensus seems to be fixated on the headline decline in Eylea, but the real risk is not near-term revenue erosion; it is whether the market remains skeptical long enough to ignore the embedded call options in late-stage assets. With multiple readouts in the next 12-24 months and buybacks stepping in as a valuation floor, the stock likely has asymmetric upside if even one or two pipeline assets land. The main reversal risk is a faster-than-expected erosion in Eylea share before Eylea HD adoption broadens, which would hit sentiment over the next 1-2 quarters even if fundamentals remain intact.

Key Decisions for Investors

• Long REGN on a 3-6 month horizon: accumulate on weakness near current levels; thesis is mid-teens earnings power with downside protected by buybacks and a diversified growth base. Expect 15-20% upside if the market re-rates it toward peer biotech multiples.
• Pair trade: long REGN / short a basket of single-franchise ophthalmology exposure over 1-2 quarters. The trade expresses Regeneron’s mix diversification and capital return strength versus names more exposed to one product’s share loss.
• Sell downside puts on REGN at 10-15% out-of-the-money with 2-4 month tenor. Risk/reward favors premium capture because the stock has a valuation floor and multiple catalysts, while implied vol may still overprice Eylea-related downside.
• If Eylea share data worsens into the next print, use that as a tactical entry rather than a thesis breaker. The market likely overreacts to one quarter of ophthalmology weakness before late-stage pipeline updates arrive.
• Avoid chasing after sharp rallies until the market sees evidence that Eylea HD can sustain offsetting growth; the cleaner entry is on any post-earnings digestion or policy-related headline volatility.